Trial of Pulse Steroid Therapy in Kawasaki Disease--Pediatric Heart Network
Status:
Completed
Trial end date:
2005-03-01
Target enrollment:
Participant gender:
Summary
The primary endpoint is coronary artery diameter, normalized for body surface area, 5 weeks
after randomization. Secondary endpoints include duration of fever, CRP levels, and adverse
events.
Phase:
Phase 3
Details
Lead Sponsor:
HealthCore-NERI New England Research Institutes
Collaborators:
National Heart, Lung, and Blood Institute (NHLBI) Pediatric Heart Network